Price T Rowe Associates Inc Geron Corp Transaction History

Price T Rowe Associates Inc

$867 Billion
Q4 2024

A detailed history of Price T Rowe Associates Inc transactions in Geron Corp stock. As of the latest transaction made, Price T Rowe Associates Inc holds 3,941,035 shares of GERN stock, worth $10.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,941,035

Previous 7,036,618 43.99%

Holding current value

$10.1 Million

Previous $31.9 Million 56.33%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$3.3 - $4.44 $10.2 Million - $13.7 Million	-3,095,583 Reduced 43.99%	3,941,035 $14 Million
Q3 2024 Nov 14, 2024	SELL	$4.17 - $4.99 $17.7 Million - $21.2 Million	-4,241,305 Reduced 37.61%	7,036,618 $31.9 Million
Q2 2024 Aug 14, 2024	BUY	$3.1 - $5.09 $28.6 Million - $46.9 Million	9,212,960 Added 446.16%	11,277,923 $47.8 Million
Q1 2024 May 15, 2024	BUY	$1.75 - $3.44 $3.29 Million - $6.46 Million	1,877,184 Added 999.68%	2,064,963 $6.82 Million
Q4 2023 Feb 14, 2024	BUY	$1.74 - $2.31 $28,711 - $38,117	16,501 Added 9.63%	187,779 $397,000
Q3 2023 Nov 14, 2023	SELL	$2.11 - $3.28 $134,734 - $209,444	-63,855 Reduced 27.16%	171,278 $364,000
Q2 2023 Aug 14, 2023	BUY	$1.97 - $3.69 $156,264 - $292,698	79,322 Added 50.91%	235,133 $755,000
Q1 2023 May 15, 2023	SELL	$2.14 - $3.4 $95,799 - $152,204	-44,766 Reduced 22.32%	155,811 $339,000
Q4 2022 Feb 14, 2023	SELL	$2.03 - $2.42 $5,507 - $6,565	-2,713 Reduced 1.33%	200,577 $485,000
Q3 2022 Nov 14, 2022	BUY	$1.67 - $2.94 $36,755 - $64,706	22,009 Added 12.14%	203,290 $476,000
Q2 2022 Aug 15, 2022	BUY	$1.19 - $1.65 $8,259 - $11,452	6,941 Added 3.98%	181,281 $281,000
Q1 2022 May 16, 2022	BUY	$0.99 - $1.6 $7,293 - $11,787	7,367 Added 4.41%	174,340 $237,000
Q4 2021 Feb 14, 2022	SELL	$1.22 - $1.72 $6,832 - $9,632	-5,600 Reduced 3.25%	166,973 $204,000
Q3 2021 Nov 15, 2021	BUY	$1.2 - $1.5 $3,411 - $4,264	2,843 Added 1.68%	172,573 $236,000
Q2 2021 Aug 16, 2021	BUY	$1.25 - $1.83 $4,443 - $6,505	3,555 Added 2.14%	169,730 $239,000
Q1 2021 May 17, 2021	SELL	$1.52 - $2.1 $44,508 - $61,492	-29,282 Reduced 14.98%	166,175 $263,000
Q4 2020 Feb 16, 2021	BUY	$1.55 - $2.05 $302,958 - $400,686	195,457 New	195,457 $311,000

Others Institutions Holding GERN

# of Institutions

306

Shares Held

465M

Call Options Held

1.07M

Put Options Held

648K

View Full List

About GERON CORP

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $971M
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

More about GERN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Geron Corp Transaction History